Research programme: nuclear receptor inhibitors - Almirall and Nuevolution

Drug Profile

Research programme: nuclear receptor inhibitors - Almirall and Nuevolution

Alternative Names: RORγt inhibitor; RORγt inverse agonist

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Nuevolution
  • Developer Almirall S.A.; Nuevolution
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 12 Dec 2016 Preclinical trials in Rheumatoid arthritis in Denmark (PO) (Nuevolution website, December 2016)
  • 12 Dec 2016 Nuclear receptor inhibitors licensed to Allmirall
  • 12 Dec 2016 Preclinical trials in Psoriatic arthritis in Denmark and Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top